Research has shown that sensory gating is largely modualted by acetylcholine. Diminished levels of acetylcholine and sensory gating deficits have been reported in research involving Alzheimer’s disease (AD) patients. However, there has been little investigation into those with a family history (FH+) of AD. The rationale of this study was to determine whether sensory gating impairments could distinguish those with early AD from individuals with increased risk for the disease while replicating previous findings of gating abnormalities in AD patients. Using the paried-click paradigm, evoked potentials were recorded from 4 groups of 20 subjects per group (AD, older controls, FH+, FH-). The results showed that while the AD group demonstrated sensory gating abnormalities, the FH+ group did not when compared to their peers with no family history of the disease (FH-). These results are discussed in relation to previous findings reporting P300 abnormalities in the FH+ group.
Hebert LE, Scherr PA, Bienias JL, et al.Alzheimer’s disease in the US population: prevalence estimates using the 2000 census. Arch Neurol.2003;60: 1119-1122.
Fumagalli F, Racagni G, Riva MA.The expanding role of BDNF: a therapeutic target for Alzheimer’s disease? Pharmacogenomics J. In press.
4.
Walker LC, Ibegbu CC, Todd CW, et al.Emerging prospects for the disease-modifying treatment of Alzheimer’s disease. Biochem Pharmacol.2005;69: 1001-1008.
5.
Bäckman L, Jones S, Berger A, et al.Cognitive impairment in preclinical Alzheimer’s disease: a meta-analysis. Neuropsychology.2005;19: 520-531.
6.
McCool MF, Varty GB, Del Vecchio RA, et al.Increased auditory startle response and reduced prepulse inhibition of startle in transgenic mice expressing a double mutant form of amyloid precursor protein. Brain Res.2003;994: 99-106.
7.
Schliebs R.Basal forebrain cholinergic dysfunction in Alzheimer’s disease—interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res.2005;6-7: 895-908.
8.
Burghaus L, Schutz U, Krempel U, et al.Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res.2000;76: 385-388.
9.
Bohnen NI, Kaufer DI, Hendrickson R, et al.Cognitive correlated of alteration in acetycholinesterase in Alzheimer’s disease. Neurosci Lett.2005;1-2: 127-132.
10.
Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, et al.Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease. Neuropsychologia.2005;43: 442-449.
11.
Cummings JL, Scheider L, Tariot PN, et al.Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease. Am J Psychiatry. 2004;161: 532-538.
12.
Mega MS, Masterson DM, O’Connor SM, et al.The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer’s disease. Arch Neurol.1999;56: 1388-1393.
13.
Minger SL, Esiri MM, McDonald B, et al.Cholinergic deficits contribute to behavioral disturbances in patients with dementia. Neurology. 2000;55: 1460-1467.
14.
Mesulam M, Shaw P, Mash D, et al.Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol.2004;55: 815-828.
15.
Herholtz K, Weisenbach S, Kalbe E, et al.Cerebral acetylcholine esterase activity in mild cognitive impairment. Neuroreport.2005;16: 1431-1434.
16.
Pekkonen E, Jaaskelainen IP, Kaakkola S, et al.Cholinergic modulation of preattentive processing in aging. Neuroimage.2005;27: 387-392.
17.
Grunwald T, Boutros NN, Pezar N, et al.Neuronal substrates of sensory gating within the human brain. Biol Psychiatry. 2003;53: 511-519.
18.
Jessen F, Kucharski C, Fries T, et al.Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer’s disease. Am J Psychiatry. 2001;158: 1319-1321.
19.
Braff DL, Geyer MA.Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry. 1990;47;181-188.
20.
Luntz-Leybman V, Bickford P, Freedman R.Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res.1992;587: 130-136.
21.
Freedman R, Hall L, Adler M, et al.Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 1995;38: 22-33.
22.
Cullum C, Harris J, Waldo M, et al.Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res.1993;10: 131-141.
23.
Jaaskelainen IP, Hirvonen J, Huttunen J, et al.Scopolomine enhances middle-latency auditory evoked magnetic fields. Neurosci Lett.1999;259: 41-44.
24.
Leonard S, Adams C, Breese CR, et al.Nicotinic receptor function in schizophrenia. Schizophr Bull.1996;22: 431-445.
25.
Freedman R, Adler LE, Myles-Worsley M, et al.Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects: human recordings, computer simulation, and an animal model. Arch Gen Psychiatry. 1996;53: 1114-1121.
26.
Buchwald JS, Erwin RJ, Read S, et al.Midlatency auditory evoked responses: differential abnormality of P1 in Alzheimer’s disease. Electroencephalogr Clin Neurophysiol. 1989;74: 378-384.
27.
Pekkonen E, Hirvonen J, Jaaskelainen IP, et al.Auditory sensory memory and the cholinergic system: implications for Alzheimer’s disease. Neuroimage.2001;14: 376-382.
28.
Green JB, Flagg L, Freed DM, et al.The middle-latency auditory evoked potential may be abnormal in dementia. Neurology. 1992;42: 1034-1036.
29.
Green JB, Burba A, Freed DM, et al.The P1 component of the middle-latency auditory potential may differentiate a brainstem group of Alzheimer’s disease. Alzheimer Dis Assoc Disord.1997;11: 153-157.
30.
Fein G, Biggins C, Van Dyke C.The auditory P50 response is normal in Alzheimer’s disease when measured via a paired click paradigm. Electroencephalogr Clin Neurophysiol. 1994;92: 536-545.
31.
Golob EJ, Miranda GG, Johnson JK, et al.Sensory cortical interactions in aging, mild cognitive impairment, and Alzheimer’s disease. Neurobiol Aging. 2001; 22: 755-763.
Devi G, Ottman R, Tang M, et al.Familial aggregation of Alzheimer’s disease among whites, African Americans, and Caribbean Hispanics in northern Manhattan. Arch Neurol.2000;57: 72-77.
34.
Reiman EM, Chen K, Alexander GE, et al.Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s disease. Proc Natl Acad Sci U S A.2004;101: 284-289.
35.
Folstein MF, Folstein SE, McHugh PR.Mini-Mental State: a practical method for grading the state of patients for the clinician. J Psychiatr Res.1975;12: 189-198.
36.
Yee CM, White PM.Experimental modification of P50 suppression. Psychophysiology.2001;38: 531-539.
37.
Jerger K, Biggins C, Fein G.P50 suppression is not affected by attentional manipulations. Biol Psychiatry. 1992;31: 365-377.
38.
Francis PT, Palmer AM, Snape M, et al.The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66: 137-147.
39.
Giannakopoulos P, Herrmann FR, Bussiere T, et al.Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology. 2003;60: 1495-1500.
40.
Morris JC, Price AL.Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer’s disease. J Mol Neurosci.2001;17: 101-118.
41.
Dekosky ST, Ikonomovic MD, Styren SD, et al.Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol.2002;51: 145-155.
42.
Kordower JH, Chu Y, Stebbins GT, et al.Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol.2001;49: 202-213.
43.
Mufson EJ, Chen EY, Cochran EJ, et al.Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol.1999;158: 469-490.
44.
Ally BA, Jones GE, Cole JA, et al.The P300 component in patients with Alzheimer’s disease and their biological children. Biol Psychol.2006;72: 180-187.
